Jci_page_head_homepage_01 Jci_page_head_homepage_02
David G. Alleva, Paul D. Crowe, Liping Jin, William W. Kwok, Nicholas Ling, Michael Gottschalk, Paul J. Conlon, Peter A. Gottlieb, Amy L. Putnam, Amitabh Gaur
Published in Volume 107, Issue 2
J Clin Invest. 2001; 107(2):173–180 doi:10.1172/JCI8525
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Example of cytokine responses to insulin B(9–23) by type 1 diabetic patients and control subjects. 3 × 105 freshly isolated PBMCs from two type 1 diabetic patients (P5 and P9) and two age-matched control subjects (C12 and C13) were seeded per well of a 96-well anti–IFN-γ mAb–coated ELISPOT assay plate in the presence or absence of insulin B(9–23) and incubated at 37°C for 24 hours. Spots representing IFN-γ–producing cells (denoted by the number in parentheses) were developed using a biotinylated anti–IFN-γ secondary antibody and avidin-labeled peroxidase with AEC substrate and quantified using the Series-1 Immunospot Analyzer.